Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"NICHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Scenic Biotech

    Menu

    Scenic Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Scenic Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

              Details:

              SC-2882 is a Scenic’s first-in-class QPCTL inhibitor, it is curently in preclinical stage where it is being evaluated as a new potential treatment approach for diffuse large B-cell lymphoma (DLBCL).

              Lead Product(s): SC-2882

              Therapeutic Area: Oncology Product Name: SC-2882

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scenic Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Typ...

              Details:

              CRADA combines Scenic Biotech’s genetic modifier platform with NIH’s patient registry to unlock genetic modifiers as a path to novel therapies for NPC disease. The goal of the collaboration is to obtain clinical insights into genes that can reduce the severity of NPC.

              Lead Product(s): Undisclosed

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: NICHD

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scenic Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease

              Details:

              Both companies, aim to identify small molecule drugs to treat Niemann Pick Type C (NP-C), a rare lipid storage disorder that affects lipid metabolism, a second undisclosed program to treat a severe heritable metabolic syndrome, and Barth syndrome program.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Barth Syndrome Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Scenic Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

              Details:

              Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Genentech

              Deal Size: $375.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY